Acilog SC Injection 100 IU/ml

Acilog SC Injection is a rapid-acting insulin analog manufactured by ACI Limited, designed to manage diabetes mellitus. Containing Insulin Aspart [Protamine Crystallised] (100 IU/ml), it mimics natural insulin to regulate blood glucose. The SC Injection form ensures precise dosing and rapid absorption, making it ideal for meal-time glucose control.

Priced at ৳825.00 per unit (5’s pack: ৳4,125.00), Acilog SC Injection requires refrigeration (2°C–8°C) to maintain efficacy. It’s contraindicated in hypoglycemia but highly effective when administered subcutaneously in the abdomen, thigh, or upper arm within 5–10 minutes before meals. Always combine with long-acting insulin for optimal results.

Key pharmacological action includes binding to insulin receptors, promoting glucose uptake in cells, and suppressing hepatic glucose production. Dosage ranges from 0.5–1.0 IU/kg/day, with adjustments based on diet, activity, or concurrent medications. Intravenous use under medical supervision is permitted for acute glycemic management.

Common side effects include hypoglycemia, allergic reactions, and injection site discomfort. Drug interactions with beta-blockers, steroids, or alcohol necessitate close monitoring. Pregnant/lactating women may use Acilog SC Injection safely under medical guidance.

For overdose management, administer glucose or glucagon for severe hypoglycemia. Explore Insulin Aspart alternatives or consult healthcare providers for personalized diabetes care strategies using this rapid-acting therapeutic solution.

Insulin Aspart has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, Insulin Aspart should generally be given immediately before a meal. When necessary Insulin Aspart may be given soon after a meal.

Dosage of Insulin Aspart is individual and determined on the basis of the physician’s advice in accordance with the needs of the patient. It should normally be used in combination with long-acting insulin given at least once a day.

The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by Insulin Aspart and the remainder by long-acting insulin. Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.

Subcutaneous Injection: Insulin Aspart should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because Insulin Aspart has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal Continuous Subcutaneous Insulin Infusion (CSII) by External Pump Insulin Aspart can also be infused subcutaneously by an external insulin pump. The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Approximately 50% of the total dose is usually given as meal-related boluses of Insulin Aspart and the remainder is given as a basal infusion. When used with an infusion pump Insulin Aspart should not be mixed with any other insulin.

Intravenous Use: Insulin Aspart can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, Insulin Aspart should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. Insulin Aspart has been shown to be stable in infusion fluids such as 0.9% sodium chloride.

Side effects of Acilog are hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus and rash.

Pregnancy category B. There are no restrictions on treatment with Protamine Crystallised Insulin Aspart during lactation. Insulin treatment of the nursing mother should not affect the baby. However, dosage may need to be adjusted.

Dose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Acilog regimens should be modified cautiously and only under medical supervision

A specific overdose for insulin cannot be defined, however, hypoglycaemia may develop over sequential stages if too high doses relative to the patient’s requirement are administered. Mild hypoglycaemic episodes can be treated by oral administration of glucose or sugary products. Severe hypoglycaemic episodes, where the patient has become unconscious, can be treated by glucagon (0.5 to 1 mg) given intramuscularly or subcutaneously. Glucose must also be given intravenously if the patient does not respond to glucagon within 10 to 15 minutes. Upon regaining consciousness administration of oral carbohydrate is recommended for the patient in order to prevent relapse.